MRD-Guided Elranatamab Maintenance Therapy

This study evaluates an individualized approach combining highly active maintenance treatment with elranatamab with peripheral blood-based clonotypic measurable residual disease (MRD) testing in patients with newly diagnosed multiple myeloma. The overall goal is to generate efficacy and tolerability data for a personalized maintenance approach using peripheral blood-based clonotypic mass spectrometry MRD testing (the EasyM assay) to guide post-autologous hematopoietic cell transplant (AHCT) maintenance with elranatamab for this patient population.